TY - JOUR
T1 - Multiple sclerosis, gut microbiota and permeability
T2 - Role of tryptophan catabolites, depression and the driving down of local melatonin
AU - Rodriguez, Moses
AU - Wootla, Bharath
AU - Anderson, George
PY - 2016
Y1 - 2016
N2 - Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.
AB - Background: Alterations in gut microbiota, coupled to increased gut permeability are now widely recognized as having a role in the etiology, course and treatment of many medical conditions, including autoimmune and neurodegenerative disorders. Methods: In this review, the role that such gut changes play over the course of multiple sclerosis (MS) is detailed. Results: Given the wide array of biological factors and processes that have been shown to be altered in MS, including changes in the gut, this allows for a better integration of the diverse array of pathophysiological processes linked to MS. Such pathophysiological processes include increases in oxidative and nitrosative stress, pro-inflammatory immune responses, especially T helper (Th)17 cell proliferation and activation, tryptophan catabolites, pain, fatigue and increased levels of depression. By raising levels of immune activation, increased gut permeability and alterations in gut microbiota impact on all of these MS-associated processes. Alterations in the regulation of local melatonergic pathway activation is proposed to be an important hub for such pathophysiological processes in MS, allowing for the increased frequency of depression that may be prodromal in MS, both in the first episode as well as in relapses, to become more intimately associated with the etiology and course of MS. We propose this occurs by decreasing serotonin availability as a precursor for the melatoninergic pathways. Conclusion: Changes in the gut are evident in the early stages of MS, including in paediatric MS, and may interact with pro-inflammatory genetic susceptibility genes to drive the biological underpinnings of MS. Such a conceptualization of the biological underpinnings of MS also has treatment implications.
KW - Depression
KW - Gut microbiota
KW - Gut permeability
KW - Immune inflammation
KW - Melatonin
KW - Multiple sclerosis
KW - Oxidative stress
KW - Pathophysiology
KW - Serotonin
KW - Th17
UR - http://www.scopus.com/inward/record.url?scp=85007543270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85007543270&partnerID=8YFLogxK
U2 - 10.2174/1381612822666160915160520
DO - 10.2174/1381612822666160915160520
M3 - Review article
C2 - 27634184
AN - SCOPUS:85007543270
SN - 1381-6128
VL - 22
SP - 6134
EP - 6141
JO - Current Pharmaceutical Design
JF - Current Pharmaceutical Design
IS - 40
ER -